Showing 2801-2810 of 3135 results for "".
- Revance: ePosters Showcase Data for DaxibotulinumtoxinA and RHA Line at Maui Dermhttps://modernaesthetics.com/news/revance-eposters-showcase-data-for-daxibotulinumtoxina-and-rha-line-at-maui-derm/2473053/Three ePosters presented at the Maui Derm for Dermatologists 2021 meeting feature data for DaxibotulinumtoxinA for Injection and the RHA® Collection of hyaluronic acid based dermal fillers, both from Revance Therapeutics. Revance repo
- Allergan Aesthetics Enters Into Option to Acquire Cypris Medicalhttps://modernaesthetics.com/news/allergan-aesthetics-enters-into-option-to-acquire-cypris-medical/2473045/Allergan Aesthetics, an AbbVie company has entered into a warrant agreement with Cypris Medical, a privately held, medical device company based in Chicago. Following the completion of a clinical trial to be initiated in 2021, Allergan Aesthetics will have the right to exercis
- Four Years Running: Alastin Leads in Growthhttps://modernaesthetics.com/news/four-years-running-alastin-leads-in-growth/2473044/Alastin Skincare®, Inc. is the Fastest Growing Brand in the US Professional Skincare Market for the fourth year in a row. That’s according to the latest rankings from consulting and research firm Kline Group's 2020 Professional Skincare: US Market Analysis and Opportunitie
- RealSelf Adds One Million Arabic-speaking Monthly Users With Tajmeeli.com Acquisitionhttps://modernaesthetics.com/news/realself-adds-1-million-arabic-speaking-monthly-users-with-tajmeelicom-acquisition/2473043/RealSelf now owns Tajmeeli, the leading cosmetic procedure resource for Arabic speaking consumers. The acquisition adds one million Arabic-speaking monthly active users. "We're excited this acquisition will enable us to expand our reach and resources to over 100 countries
- Melasma Update: Studies Show Benefit with Cysperahttps://modernaesthetics.com/news/melasma-update-studies-show-benefit-with-cyspera/2473042/Several studies recently published in peer reviewed journals demonstrate the safety and efficacy of stabilized-cysteamine 5% cream (Cyspera), the novel, non-hydroquinone, topical pigment regulator from Scientis In a randomized, double-blinded study of 50 melasma patients assigned to eit
- Merz and Candela Announce New Collabhttps://modernaesthetics.com/news/merz-and-candela-announce-new-collab/2473041/Merz Aesthetics and Candela Corporation are joining forces. As part of the collab, sales reprentatives from each company will now have the ability to promote products from both organizations. The companies are not formally changing their structure or formally integr
- Cynosure Hires Katie Cheng As New CMOhttps://modernaesthetics.com/news/cynosure-hires-katie-cheng-as-new-chief-marketing-office/2473038/Katie Cheng is Cynosure’s new Chief Marketing Officer. "Katie's proven track record of consumer and professional marketing strategy and execution is one of the many reasons we are eager to have Katie join our team," says Cynosure CEO Todd Tillemans, i
- Expert Sets Record Straight on COVID-19 Vaccine/Fillers “Risk”https://modernaesthetics.com/news/expert-sets-record-straight-on-covid-19-vaccinefillers-risk/2473033/When FDA officials reviewed the data for Moderna’s COVID-19 vaccine, a data point garnered some attention. There seemed to be at least a temporal association between treatment with dermal fillers and non-serious adverse reactions to the vaccine in three study subjects. Modern Aesth
- 2020 in Reviewhttps://modernaesthetics.com/news/2020-in-review-1/2473031/• The AmSpa Aesthetic Safety Council (AASC), designed to help the American Med Spa Association (AmSpa) further its goal of promoting compliance, safety, and profitability throughout the medical aesthetic industry, has launched. Even in the midst of the international COVI
- Developing Story: AbbVie’s Allergan Wins Trade Secret Case Against Evolushttps://modernaesthetics.com/news/developing-story-abbvies-allergan-wins-trade-secret-case-against-evolus/2473030/AbbVie Inc.’s Allergan won a U.S. trade agency order to block Evolus Inc. and its partner Daewoong Pharmaceutical Co. from importing Jeuveau into the U.S. for 21 months, according to media reports. The U.S. International Trade Commission upheld a judge’s findings that Jeuvea